SI20109A - Stabilna farmacevtska formulacija - Google Patents

Stabilna farmacevtska formulacija Download PDF

Info

Publication number
SI20109A
SI20109A SI9800309A SI9800309A SI20109A SI 20109 A SI20109 A SI 20109A SI 9800309 A SI9800309 A SI 9800309A SI 9800309 A SI9800309 A SI 9800309A SI 20109 A SI20109 A SI 20109A
Authority
SI
Slovenia
Prior art keywords
pharmaceutical formulation
solid pharmaceutical
active ingredient
pravastatin
formulation according
Prior art date
Application number
SI9800309A
Other languages
English (en)
Slovenian (sl)
Inventor
Janez Ker
Original Assignee
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. filed Critical LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.
Priority to SI9800309A priority Critical patent/SI20109A/sl
Priority to JP2000587746A priority patent/JP2002532409A/ja
Priority to DE69937691T priority patent/DE69937691T2/de
Priority to CZ20011727A priority patent/CZ302562B6/cs
Priority to SK809-2001A priority patent/SK8092001A3/sk
Priority to PL99347686A priority patent/PL347686A1/xx
Priority to PCT/IB1999/001749 priority patent/WO2000035425A1/en
Priority to YU35501A priority patent/YU35501A/sh
Priority to SI9931000T priority patent/SI1148872T1/sl
Priority to CA002348988A priority patent/CA2348988C/en
Priority to HU0104258A priority patent/HUP0104258A3/hu
Priority to AT99951034T priority patent/ATE380020T1/de
Priority to CNB998144037A priority patent/CN1198597C/zh
Priority to EP99951034A priority patent/EP1148872B1/en
Priority to TR2001/01235T priority patent/TR200101235T2/xx
Priority to IL14375999A priority patent/IL143759A0/xx
Priority to NZ511260A priority patent/NZ511260A/xx
Priority to ES99951034T priority patent/ES2299265T3/es
Priority to KR1020017006808A priority patent/KR100638307B1/ko
Priority to EP07122298A priority patent/EP1911445A3/en
Priority to AU63608/99A priority patent/AU775946B2/en
Priority to US09/600,436 priority patent/US6680341B1/en
Priority to RU2001115716/15A priority patent/RU2227019C2/ru
Publication of SI20109A publication Critical patent/SI20109A/sl
Priority to HR20010325A priority patent/HRP20010325A2/hr
Priority to ZA200103802A priority patent/ZA200103802B/en
Priority to IS5939A priority patent/IS5939A/is
Priority to BG105559A priority patent/BG105559A/xx
Priority to IL143759A priority patent/IL143759A/en
Priority to US10/655,263 priority patent/US20040072894A1/en
Priority to US12/172,143 priority patent/US20090264497A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
SI9800309A 1998-12-16 1998-12-16 Stabilna farmacevtska formulacija SI20109A (sl)

Priority Applications (30)

Application Number Priority Date Filing Date Title
SI9800309A SI20109A (sl) 1998-12-16 1998-12-16 Stabilna farmacevtska formulacija
IL14375999A IL143759A0 (en) 1998-12-16 1999-10-29 STABLE PHARMACEUTICAL FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITORS
NZ511260A NZ511260A (en) 1998-12-16 1999-10-29 Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitor
DE69937691T DE69937691T2 (de) 1998-12-16 1999-10-29 Stabile arzneiformulierungen enthaltend pravastatin oder atorvastatin
SK809-2001A SK8092001A3 (en) 1998-12-16 1999-10-29 Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
PL99347686A PL347686A1 (en) 1998-12-16 1999-10-29 Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
PCT/IB1999/001749 WO2000035425A1 (en) 1998-12-16 1999-10-29 STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
YU35501A YU35501A (sh) 1998-12-16 1999-10-29 STABILNA FARMACEUTSKA FORMULACIJA KOJA UKLJUČUJE INHIBITOR HMG-CoA REDUKTAZE
SI9931000T SI1148872T1 (sl) 1998-12-16 1999-10-29 Stabilna farmacevtska formulacija vsebujoca pravastatin ali atorvastatin
CA002348988A CA2348988C (en) 1998-12-16 1999-10-29 Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
HU0104258A HUP0104258A3 (en) 1998-12-16 1999-10-29 Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
AT99951034T ATE380020T1 (de) 1998-12-16 1999-10-29 Stabile arzneiformulierungen enthaltend pravastatin or atorvastatin
CNB998144037A CN1198597C (zh) 1998-12-16 1999-10-29 包含HMG－CoA还原酶抑制剂的稳定的药物配方
EP99951034A EP1148872B1 (en) 1998-12-16 1999-10-29 Stable pharmaceutical formulation comprising pravastatin or atorvastatin
TR2001/01235T TR200101235T2 (tr) 1998-12-16 1999-10-29 HMG-CoA Redüktaz inhibitörü içeren durağan farmasötik formül
JP2000587746A JP2002532409A (ja) 1998-12-16 1999-10-29 ＨＭＧ−ＣｏＡレダクターゼインヒビターを含む安定な薬学的処方物
CZ20011727A CZ302562B6 (cs) 1998-12-16 1999-10-29 Stabilizovaná farmaceuticky aktivní substance obsahující inhibitor HMG-CoA reduktázy
ES99951034T ES2299265T3 (es) 1998-12-16 1999-10-29 Formulacion farmaceutica estable que incluye pravastatina o atorvastatina.
KR1020017006808A KR100638307B1 (ko) 1998-12-16 1999-10-29 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 안정한 약학적조제물
EP07122298A EP1911445A3 (en) 1998-12-16 1999-10-29 Stable pharmaceutical formulation comprising an HMG-COA reductase inhibitor
AU63608/99A AU775946B2 (en) 1998-12-16 1999-10-29 Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitor
US09/600,436 US6680341B1 (en) 1998-12-16 1999-10-29 Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitor
RU2001115716/15A RU2227019C2 (ru) 1998-12-16 1999-10-29 Твердый фармацевтический препарат, содержащий ингибитор hmg-coa-редуктазы
HR20010325A HRP20010325A2 (en) 1998-12-16 2001-05-07 STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
ZA200103802A ZA200103802B (en) 1998-12-16 2001-05-10 Stable pharmaceutical formulation comprising HMG-CoA reductase inhibitor.
IS5939A IS5939A (is) 1998-12-16 2001-05-15 Stöðug lyfjablanda sem inniheldur HMG-CoA redúktasahemil
BG105559A BG105559A (en) 1998-12-16 2001-06-04 STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
IL143759A IL143759A (en) 1998-12-16 2001-06-14 Stable pharmaceutical formulation containing HMG COA REDUCTASE inhibitor
US10/655,263 US20040072894A1 (en) 1998-12-16 2003-09-04 Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitor
US12/172,143 US20090264497A1 (en) 1998-12-16 2008-07-11 Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI9800309A SI20109A (sl) 1998-12-16 1998-12-16 Stabilna farmacevtska formulacija

Publications (1)

Publication Number Publication Date
SI20109A true SI20109A (sl) 2000-06-30

Family

ID=20432372

Family Applications (2)

Application Number Title Priority Date Filing Date
SI9800309A SI20109A (sl) 1998-12-16 1998-12-16 Stabilna farmacevtska formulacija
SI9931000T SI1148872T1 (sl) 1998-12-16 1999-10-29 Stabilna farmacevtska formulacija vsebujoca pravastatin ali atorvastatin

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI9931000T SI1148872T1 (sl) 1998-12-16 1999-10-29 Stabilna farmacevtska formulacija vsebujoca pravastatin ali atorvastatin

Country Status (25)

Country Link
US (3) US6680341B1 (is)
EP (2) EP1148872B1 (is)
JP (1) JP2002532409A (is)
KR (1) KR100638307B1 (is)
CN (1) CN1198597C (is)
AT (1) ATE380020T1 (is)
AU (1) AU775946B2 (is)
BG (1) BG105559A (is)
CA (1) CA2348988C (is)
CZ (1) CZ302562B6 (is)
DE (1) DE69937691T2 (is)
ES (1) ES2299265T3 (is)
HR (1) HRP20010325A2 (is)
HU (1) HUP0104258A3 (is)
IL (2) IL143759A0 (is)
IS (1) IS5939A (is)
NZ (1) NZ511260A (is)
PL (1) PL347686A1 (is)
RU (1) RU2227019C2 (is)
SI (2) SI20109A (is)
SK (1) SK8092001A3 (is)
TR (1) TR200101235T2 (is)
WO (1) WO2000035425A1 (is)
YU (1) YU35501A (is)
ZA (1) ZA200103802B (is)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
USRE44578E1 (en) 2000-04-10 2013-11-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
CA2406574C (en) 2000-04-10 2006-12-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
WO2001093859A1 (en) † 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stable pharmaceutical product and formulation
US6531507B1 (en) * 2000-06-09 2003-03-11 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US20050215636A1 (en) * 2000-10-05 2005-09-29 Vilmos Keri Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
KR20030096294A (ko) * 2001-03-27 2003-12-24 랜박시 래보러터리스 리미티드 프라바스타틴의 안정한 약학적 조성물
GB0111077D0 (en) * 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
EP1404301A4 (en) * 2001-06-21 2006-03-22 Andrx Pharmaceuticals Inc PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED RELEASE, STABLE, CONTAINING PRAVASTATIN
JP2003055217A (ja) * 2001-08-10 2003-02-26 Taiyo Yakuhin Kogyo Kk 医薬組成物
EP1905431A1 (en) * 2002-01-11 2008-04-02 Circ Pharma Research and Development Limited Pravastatin pharmaceutical formulations and methods of their use
WO2003057195A1 (en) * 2002-01-11 2003-07-17 Athpharma Limited Pravastatin pharmaceutical formulations and methods of their use
MXPA04007905A (es) * 2002-02-14 2004-11-26 Ranbaxy Lab Ltd Formulaciones de atorvastatin estabilizadas con adiciones de metal alcali.
CA2385529A1 (en) * 2002-05-21 2003-11-21 Bernard Charles Sherman Stable dosage forms comprising atorvastatin calcium
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
US20040132806A1 (en) * 2002-09-03 2004-07-08 Jackie Butler Pravastatin pharmaceutical formulations and methods of their use
CA2509688A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
US20050271717A1 (en) 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US8163797B2 (en) * 2003-12-31 2012-04-24 Actavis Elizabeth Llc Method of treating with stable pravastatin formulation
WO2005084669A1 (en) * 2004-03-01 2005-09-15 Lek Pharmaceuticals D.D. Pharmaceutical composition
KR100598326B1 (ko) 2004-04-10 2006-07-10 한미약품 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
WO2006008757A2 (en) * 2004-05-05 2006-01-26 Cadila Healthcare Limited Stabilized pharmaceutical compositions of pravastatin
MX2007001558A (es) * 2004-08-06 2008-03-13 Transform Pharmaceuticals Inc Formulaciones novedosas de fenofibrato y metodos de tratamiento relacionados.
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
EP1786414A4 (en) * 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES
US20090208539A1 (en) * 2004-11-22 2009-08-20 Adel Penhasi Stable atorvastatin formulations
US20060229277A1 (en) * 2005-04-08 2006-10-12 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
CA2615941A1 (en) * 2005-08-05 2007-02-15 Orbus Pharma Inc. Stabilized extended release pharmeceutical compositions comprising an hmg-coa reductase inhibitor
US20090247603A1 (en) * 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
US20080038332A1 (en) * 2006-08-10 2008-02-14 Cai Gu Huang Stable pharmaceutical formulation comprising atorvastatin calcium
HU227610B1 (en) * 2006-09-18 2011-09-28 Richter Gedeon Nyrt Pharmaceutical compositions containing rosuvastatin potassium
WO2008062476A2 (en) * 2006-10-31 2008-05-29 Glenmark Pharmaceutical Limited Pharmaceutical composition comprising rosuvastatin or pharmaceutically accepatble salts thereof
BG934U1 (bg) * 2006-12-14 2007-11-30 "Софарма" Ад Състав за твърда лекарствена форма, съдържащ правастатин
AU2007355452B2 (en) * 2007-06-25 2011-12-15 Pharmathen S.A. Improved pharmaceutical formulation containing an HMG-CoA reductase inhibitor and method for the preparation thereof
GB0713707D0 (en) * 2007-07-13 2007-08-22 Generics Uk Ltd Stable compositions
WO2009024889A2 (en) 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
DE102007052071A1 (de) 2007-10-30 2009-05-07 Stada Arzneimittel Ag Stabilisiertes Atorvastatin
JPWO2011049122A1 (ja) * 2009-10-21 2013-03-14 第一三共株式会社 プラバスタチンナトリウム口腔内速崩壊錠及びその製造方法
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
KR101248804B1 (ko) * 2010-05-14 2013-03-29 한미사이언스 주식회사 ＨＭＧ-ＣｏＡ 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제
TR201005326A2 (tr) 2010-06-30 2012-01-23 Bi̇lgi̇ç Mahmut Çoklu dozaj formları.
US8609138B2 (en) * 2010-06-30 2013-12-17 Mochida Pharmaceutical Co., Ltd. ω3 fatty acid compound preparation
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
WO2012141160A1 (ja) * 2011-04-12 2012-10-18 沢井製薬株式会社 ピタバスタチン含有製剤及びその製造方法
WO2012153181A1 (en) * 2011-05-11 2012-11-15 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical composition comprising pitavastatin or its pharmaceutically acceptable salts
WO2012170417A2 (en) 2011-06-06 2012-12-13 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
IN2014CN04119A (is) 2011-11-15 2015-07-10 Reddys Lab Ltd Dr
KR20140030505A (ko) * 2012-08-31 2014-03-12 한미약품 주식회사 이베살탄 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
KR101597004B1 (ko) 2013-07-25 2016-02-23 씨제이헬스케어 주식회사 서방형 메트포르민과 속방형 HMG-CoA 환원효소 억제제를 포함하는 복합제제
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
CN109044989A (zh) * 2018-10-09 2018-12-21 河南师范大学 一种阿托伐他汀钙胶囊制剂及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US579837A (en) * 1897-03-30 Saw-sharpening machine
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
CA2150372C (en) 1993-01-19 2002-08-20 Nancy L. Mills Stable oral ci-981 formulation and process of preparing same
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
CZ288545B6 (cs) * 1995-12-22 2001-07-11 Kowa Company, Ltd. Stabilizovaná farmaceutická kompozice na bázi kyseliny (E)-3,5-dihydroxy-7-[4´-4´´-fluorfenyl-2´-cyklopropylchinolin-3´-yl]-6-heptenové
FR2751316B1 (fr) * 1996-07-19 1998-08-28 Granger Maurice Appareil distributeur de bandes de papier ouate pour essuie-mains, papier toilette et similaire
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6531507B1 (en) * 2000-06-09 2003-03-11 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
SI21302A (sl) * 2002-10-11 2004-04-30 LEK farmacevtska dru�ba d.d. Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
TW589178B (en) * 2003-02-21 2004-06-01 China Chemical & Pharmaceutica A novel industrial process to obtain pravastatin sodium of high purity

Also Published As

Publication number Publication date
CN1330538A (zh) 2002-01-09
US6680341B1 (en) 2004-01-20
CN1198597C (zh) 2005-04-27
AU775946B2 (en) 2004-08-19
DE69937691D1 (de) 2008-01-17
BG105559A (en) 2001-12-29
SI1148872T1 (sl) 2008-04-30
US20040072894A1 (en) 2004-04-15
HRP20010325A2 (en) 2002-06-30
DE69937691T2 (de) 2008-11-20
ZA200103802B (en) 2002-06-10
CZ302562B6 (cs) 2011-07-13
IL143759A0 (en) 2002-04-21
RU2227019C2 (ru) 2004-04-20
US20090264497A1 (en) 2009-10-22
IS5939A (is) 2001-05-15
HUP0104258A2 (hu) 2002-03-28
JP2002532409A (ja) 2002-10-02
EP1911445A2 (en) 2008-04-16
EP1148872B1 (en) 2007-12-05
KR100638307B1 (ko) 2006-10-25
EP1148872A1 (en) 2001-10-31
CA2348988C (en) 2009-07-21
ES2299265T3 (es) 2008-05-16
IL143759A (en) 2006-08-01
PL347686A1 (en) 2002-04-22
NZ511260A (en) 2004-01-30
YU35501A (sh) 2005-07-19
CZ20011727A3 (cs) 2001-09-12
KR20010101105A (ko) 2001-11-14
EP1911445A3 (en) 2011-04-27
ATE380020T1 (de) 2007-12-15
HUP0104258A3 (en) 2002-11-28
AU6360899A (en) 2000-07-03
SK8092001A3 (en) 2001-10-08
CA2348988A1 (en) 2000-06-22
TR200101235T2 (tr) 2001-10-22
WO2000035425A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
SI20109A (sl) Stabilna farmacevtska formulacija
AU2000249434B2 (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
AU2000249434A1 (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US20070202159A1 (en) Pharmaceutical composition comprising stabilized statin particles
SI21402A (sl) Obloženi delci in farmacevtske oblike
JP2004501121A5 (is)
CA2692862C (en) Stable compositions
US6806290B2 (en) Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
SI21400A (sl) Stabilna farmacevtska oblika z inhibitorjem HMG-CoA reduktaze
MXPA01012225A (es) Formulaciones novedosas que comprenden agentes reguladores de lipido.

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20090303